Genomic Profiling Systems, Inc. Names New CEO To Drive Commercialization Of Growth Direct(TM) System To The Pharmaceutical Manufacturing Industry
Published: Apr 10, 2006
BEDFORD, Mass.--(BUSINESS WIRE)--April 10, 2006--Genomic Profiling Systems, a privately held company focused on rapid microbiology innovations for pharmaceutical production, today announced the appointment of Stephen H. Delity to the position of CEO. Delity brings a proven track record of growing sales and profits in laboratory instrument markets, while serving as a Vice President and Business Unit Leader at PerkinElmer Life and Analytical Sciences in Shelton, CT.
"The Board of Directors and I are extremely pleased to have Steve lead GPS at this exciting stage in our company's growth", commented Don Straus Ph.D., company founder and CSO. "Steve brings an impressive track record of success in developing and executing profitable business strategies. His extensive experience in launching new capital equipment products into the pharmaceutical manufacturing and QA/QC market segment is particularly important as we prepare to launch our Growth Direct(TM) system. Furthermore, Steve is an energetic and accomplished leader with a talent for building effective organizations."
Delity added "Genomic Profiling Systems is on the brink of dramatically improving the economics of manufacturing in the pharmaceutical, food and beverage and personal care industries by launching its revolutionary Growth Direct(TM) System, which will significantly reduce the time required to test for microbial contaminants. I am delighted to lead a developing world-class organization, built on deep expertise in applied microbiology and customer commitment."
Delity's professional background encompasses engineering, strategy, business development and leadership. While at PerkinElmer, he drove business unit sales growth at two to three times the market rate while significantly increasing operating profit. Prior to his position with PerkinElmer, Delity was a Consultant with McKinsey & Company, a Field Project Manager for M.W. Kellogg Company and served as an Officer in the US Army.
Steve holds an MBA from Harvard Business School, an MS in Systems Management from Golden Gate University in San Francisco, CA and a BS in Mechanical Engineering from the United States Military Academy at West Point.
About Genomic Profiling Systems
Genomic Profiling Systems, based in Bedford, MA, is a privately held company developing groundbreaking products that address significant unmet needs in pharmaceutical manufacturing, the food industry, healthcare, and biodefense global markets. The Company's automated testing platforms and products deliver rapid, ultra-sensitive detection of microbiological contamination, infection, and disease markers. In the fourth quarter of 2006, GPS will launch its first product, the Growth Direct(TM) System, which rapidly detects microbiological contamination in pharmaceutical products. This new tool will help pharmaceutical manufacturers improve their manufacturing efficiencies in accordance with the FDA's Process Analytical Technology (PAT) initiative. For more information, go to www.genprosys.com.
MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5120515
Contact: Genomic Profiling Systems Steve Delity, 781-271-1444 info@genprosys.com
Source: Genomic Profiling Systems